JP2023500573A5 - - Google Patents

Info

Publication number
JP2023500573A5
JP2023500573A5 JP2022520658A JP2022520658A JP2023500573A5 JP 2023500573 A5 JP2023500573 A5 JP 2023500573A5 JP 2022520658 A JP2022520658 A JP 2022520658A JP 2022520658 A JP2022520658 A JP 2022520658A JP 2023500573 A5 JP2023500573 A5 JP 2023500573A5
Authority
JP
Japan
Prior art keywords
polypeptide
pharmaceutical composition
composition according
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022520658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500573A (ja
JP7901416B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/056901 external-priority patent/WO2021081232A1/en
Publication of JP2023500573A publication Critical patent/JP2023500573A/ja
Publication of JP2023500573A5 publication Critical patent/JP2023500573A5/ja
Application granted granted Critical
Publication of JP7901416B2 publication Critical patent/JP7901416B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022520658A 2019-10-23 2020-10-22 改変された細胞傷害性t細胞及びその使用方法 Active JP7901416B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962925111P 2019-10-23 2019-10-23
US62/925,111 2019-10-23
PCT/US2020/056901 WO2021081232A1 (en) 2019-10-23 2020-10-22 Modified cytotoxic t cells and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2023500573A JP2023500573A (ja) 2023-01-10
JP2023500573A5 true JP2023500573A5 (cg-RX-API-DMAC7.html) 2023-10-25
JP7901416B2 JP7901416B2 (ja) 2026-08-06

Family

ID=75620832

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520658A Active JP7901416B2 (ja) 2019-10-23 2020-10-22 改変された細胞傷害性t細胞及びその使用方法

Country Status (8)

Country Link
US (2) US20230000914A1 (cg-RX-API-DMAC7.html)
EP (1) EP4048402A4 (cg-RX-API-DMAC7.html)
JP (1) JP7901416B2 (cg-RX-API-DMAC7.html)
CN (1) CN114423497A (cg-RX-API-DMAC7.html)
AU (1) AU2020369573A1 (cg-RX-API-DMAC7.html)
CA (1) CA3146903A1 (cg-RX-API-DMAC7.html)
IL (1) IL290297A (cg-RX-API-DMAC7.html)
WO (1) WO2021081232A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110325205B (zh) 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR20240005989A (ko) 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
WO2019051127A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ, インコーポレイテッド 1型真性糖尿病(t1d)を治療するためのmhcクラスii t細胞調節多量体ポリペプチド及びその使用方法
CN119365484A (zh) * 2022-04-28 2025-01-24 Cue生物制药股份有限公司 修饰的细胞毒性t细胞及其使用方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675204B2 (en) * 1992-06-25 1997-01-30 City Of Hope Induction of cytolytic T-lymphocytes with cytomegalovirus polypeptides
US20020151690A1 (en) 1997-08-12 2002-10-17 Luxemburg Alain T Purification of antigen-specific t cells
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗cd19抗体
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CA2644712C (en) 2006-03-06 2016-09-13 Amunix, Inc. Unstructured recombinant polymers and uses thereof
CA2695374A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
HRP20150074T1 (hr) 2007-10-01 2015-03-13 Bristol-Myers Squibb Company Humana antitijela koja se vežu za mezotelin i njihove uporabe
KR101559599B1 (ko) 2007-11-26 2015-10-12 바이엘 인텔렉쳐 프로퍼티 게엠베하 항-메소텔린 항체 및 이의 용도
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
JP2012504961A (ja) 2008-10-06 2012-03-01 ミネルバ バイオテクノロジーズ コーポレーション Muc1*抗体
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
CA2756393C (en) 2009-03-24 2017-06-20 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Anti-mesothelin antibodies
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
SG194567A1 (en) 2011-04-21 2013-12-30 Seattle Genetics Inc Novel binder-drug conjugates (adcs) and their use
WO2014031476A1 (en) 2012-08-21 2014-02-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Bcma抗原結合蛋白質
IL305629A (en) 2013-02-15 2023-11-01 Univ California Chimeric antigen receptor and methods of using it
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
CN122399016A (zh) 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
JP6652932B2 (ja) * 2014-06-18 2020-02-26 アルバート アインシュタイン カレッジ オブ メディシン synTacポリペプチド及びその使用
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
UY36401A (es) 2014-11-14 2016-06-30 Novartis Ag Conjugados anticuerpos-fármacos
EP3256494A4 (en) 2015-02-10 2018-12-05 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
KR102618312B1 (ko) 2015-03-17 2023-12-28 메모리얼 슬로안 케터링 캔서 센터 항muc16 항체 및 그의 용도
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
ES2913208T3 (es) 2015-12-01 2022-06-01 Glaxosmithkline Ip Dev Ltd Tratamientos de combinación y usos y métodos de los mismos
PT3393504T (pt) 2015-12-22 2025-12-30 Novartis Ag Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
CN113082201B (zh) * 2016-04-01 2024-07-05 上海斯丹赛生物技术有限公司 刺激t细胞介导的对表达抗原的细胞群的免疫应答的方法
JP7002769B2 (ja) 2016-09-16 2022-02-04 ベイラー カレッジ オブ メディスン ウイルス特異的t細胞の活性化および拡大のためのプラットフォーム
KR102531251B1 (ko) 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
DE102016225436A1 (de) * 2016-12-19 2018-06-21 Volkswagen Aktiengesellschaft Sensor zum Erfassen von Messwerten, Verfahren, Vorrichtung und computerlesbares Speichermedium mit Instruktionen zur Verarbeitung von Messwerten eines Sensors
CN110325205B (zh) 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
WO2018129270A1 (en) * 2017-01-05 2018-07-12 Fred Hutchinson Cancer Research Center Systems and methods to improve vaccine efficacy
EP3755711A4 (en) * 2018-02-20 2021-11-24 Technion Research & Development Foundation Limited IMMUNOTHERAPEUTIC COMPOSITION FOR THE TREATMENT OF CANCER
KR20220015382A (ko) 2019-05-29 2022-02-08 큐 바이오파마, 인크. 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법

Similar Documents

Publication Publication Date Title
JP2023500574A5 (cg-RX-API-DMAC7.html)
JP2022534846A5 (cg-RX-API-DMAC7.html)
JP2022515331A5 (cg-RX-API-DMAC7.html)
JP2021525509A5 (cg-RX-API-DMAC7.html)
JP2023518049A5 (cg-RX-API-DMAC7.html)
CN108884140B (zh) 修饰的嵌合受体及相关组合物和方法
JP2020506962A5 (cg-RX-API-DMAC7.html)
JP2022536581A5 (cg-RX-API-DMAC7.html)
NZ759969A (en) Tagged chimeric effector molecules and receptors thereof
EP3169703B1 (en) Chimeric antigen receptor and its use
JP2017501702A5 (cg-RX-API-DMAC7.html)
IL272085B (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
JP2019513347A5 (cg-RX-API-DMAC7.html)
JP2021519301A5 (cg-RX-API-DMAC7.html)
RU2017121115A (ru) Генетически модифицированные гамма дельта т-клетки
JP2019516665A5 (cg-RX-API-DMAC7.html)
JP2018525033A5 (cg-RX-API-DMAC7.html)
WO2013185552A1 (zh) 双信号独立的嵌合抗原受体及其用途
RU2017129591A (ru) МАт-НАПРАВЛЯЕМЫЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРНЫЕ СИСТЕМЫ ДЛЯ СОРТИРОВКИ/ИСТОЩЕНИЯ СКОНСТРУИРОВАННЫХ ИММУННЫХ КЛЕТОК
US20260053855A1 (en) Modified Cytotoxic T Cells and Methods of Use Thereof
JP2021534740A5 (cg-RX-API-DMAC7.html)
JP2019535262A5 (cg-RX-API-DMAC7.html)
JP2019527041A5 (cg-RX-API-DMAC7.html)
JP2022515330A5 (cg-RX-API-DMAC7.html)
JP2024541334A5 (cg-RX-API-DMAC7.html)